1. Home
  2. TURN vs DXR Comparison

TURN vs DXR Comparison

Compare TURN & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TURN
    SELLHOLDBUYas of 18 hours ago
  • DXR
    SELLHOLDBUYas of 18 hours ago
  • Stock Information
  • Founded
  • TURN 1981
  • DXR 1970
  • Country
  • TURN United States
  • DXR United States
  • Employees
  • TURN N/A
  • DXR N/A
  • Industry
  • TURN Finance/Investors Services
  • DXR Medical/Dental Instruments
  • Sector
  • TURN Finance
  • DXR Health Care
  • Exchange
  • TURN Nasdaq
  • DXR Nasdaq
  • Market Cap
  • TURN N/A
  • DXR 40.3M
  • IPO Year
  • TURN N/A
  • DXR N/A
  • Fundamental
  • Price
  • TURN $3.91
  • DXR $7.92
  • Analyst Decision
  • TURN
  • DXR Strong Buy
  • Analyst Count
  • TURN 0
  • DXR 1
  • Target Price
  • TURN N/A
  • DXR $25.00
  • AVG Volume (30 Days)
  • TURN 52.6K
  • DXR 9.1K
  • Earning Date
  • TURN 05-12-2025
  • DXR 01-01-0001
  • Dividend Yield
  • TURN N/A
  • DXR N/A
  • EPS Growth
  • TURN N/A
  • DXR 86.16
  • EPS
  • TURN N/A
  • DXR 0.11
  • Revenue
  • TURN $194,813.00
  • DXR $119,714.00
  • Revenue This Year
  • TURN N/A
  • DXR N/A
  • Revenue Next Year
  • TURN N/A
  • DXR N/A
  • P/E Ratio
  • TURN N/A
  • DXR $74.89
  • Revenue Growth
  • TURN 254.25
  • DXR N/A
  • 52 Week Low
  • TURN $3.12
  • DXR $6.55
  • 52 Week High
  • TURN $4.30
  • DXR $10.00
  • Technical
  • Relative Strength Index (RSI)
  • TURN 50.88
  • DXR 48.18
  • Support Level
  • TURN $3.87
  • DXR $8.02
  • Resistance Level
  • TURN $4.00
  • DXR $8.24
  • Average True Range (ATR)
  • TURN 0.15
  • DXR 0.40
  • MACD
  • TURN 0.01
  • DXR -0.03
  • Stochastic Oscillator
  • TURN 78.46
  • DXR 0.00

Stock Price Comparison Chart: TURN vs DXR

TURN
DXR
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April0246810121416TURN VS DXR

About DXR Daxor Corporation

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use